Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by Thao977on Mar 01, 2019 7:03am

182 Views

Post# 29427340

Marie-Noel Colussi exerciced option

Filings by transaction date Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-1,900 Price:$9.14 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-1,100 Price:$9.18 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-500 Price:$9.16 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-2,500 Price:$9.15 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-3,000 Price:$9.15 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-3,000 Price:$9.16 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:10 - Acquisition or disposition in the public market # or value acquired/disposed of:-3,000 Price:$9.17 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Common Shares Nature of Transaction:51 - Exercise of options # or value acquired/disposed of:15,000 Price:$1.80 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Options Nature of Transaction:51 - Exercise of options # or value acquired/disposed of:-15,000 Price:$1.80 Feb 26, 2019 (filed on Feb 28, 2019) Insider Name:Colussi, Marie-Nol Ownership Type:Direct Ownership Securities:Options Nature of Transaction:50 - Grant of options # or value acquired/disposed of:17,800 Price:$8.76

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features